Buy Like Buffett
Watchlist

Flagship explainer

How PUMA BIOTECHNOLOGY, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$228M · 100%Cost of revenue$58.2M · 25%Gross profit$170M · 75%Operating income$37.3M · 16%Income before tax$35.8M · 16%Income tax$4.7M · 2%Net income$31.1M · 14%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$228M100%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
Cost of revenue$58.2M25%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
$170M75%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
$37.3M16%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
Income before tax$35.8M16%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
Income tax$4.7M2%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
$31.1M14%
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001437749-26-005891 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 15, 2026 · annual-row source set
Embed this chart

View the full PUMA BIOTECHNOLOGY, INC. analysis at Buy Like Buffett